Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011206 (delirium)
 5,996 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Many agents are available for sedation of agitated, delirious patients. In general, they should be administered intravenously to achieve a painless, more rapid, and more reliable onset of action. Proper selection of an agent requires understanding the basic principles discussed in this article, including the T-1/2 alpha and T-1/2 beta and the side-effect profile associated with each class of drugs, as well as for each agent. As a group, BNZs tend to be the safest and most predictable, and can be titrated easily when administered intravenously. Neuroleptic agents such as haloperidol may act synergistically with BNZs, resulting in control of agitation without significantly depressing the patient's level of consciousness or respiratory drive. Barbiturates, highly effective sedatives, more profoundly depress the respiratory and cardiovascular systems, and probably should be reserved for the severely agitated patient who cannot be controlled otherwise. Etomidate and propofol, useful for short-term procedures, probably should be avoided for long-term use in the agitated patient because of potentially serious side effects. Opioids should be used to provide adequate pain relief and to supplement other sedatives. Inadequate doses or dosing regimens should be avoided. Once sedation has been achieved, control usually can be maintained with continuous intravenous infusions of BNZs, perhaps in combination with a continuous infusion of an opioid or intermittent administration of a neuroleptic agent. With goal-oriented titration of the pharmacologic therapy, patients can be maintained safely in a sedate, calm state; intermittent periods of agitation, alternating with periods of severely depressed level of consciousness, can be avoided. Finally, when pharmacologic suppression of agitation and delirium is needed, the patient must be evaluated fully to determine the underlying cause of the confusional state.
 ...
PMID:Pharmacology of intravenous sedatives and opioids in critically ill patients. 800 Sep 23

Delirium is a state of disturbed consciousness and attention and cognition or perception, which develops acutely, fluctuates during the course of the day, and is attributable to a physical disorder. This syndrome is the focus of increasing attention in light of emerging evidence of its enormous impact in human suffering as well as patient care costs. As currently conceptualized, delirium is a threshold phenomenon in which systemic and cerebral insults are cumulative and, in most cases, are multifactorial in origin. Because delirium results from an underlying medical condition, its prognosis is dependent largely on how quickly that condition is identified and appropriately treated. A basic algorithm for initial delirium management is reviewed, which includes discontinuing noncritical medications, instituting close observation, monitoring vital signs and fluid intake and output, obtaining a complete history, performing initial laboratory studies to determine the causes, implementing environmental and psychosocial interventions, and instituting pharmacologic treatment as indicated for agitation and psychosis. The pharmacologic treatment of choice is an antipsychotic of the butyrophenone class. Benzodiazepine use is reserved for the specific treatment of alcohol and sedative withdrawal, and for adjunctive use with antipsychotic agents in treatment-refractory cases. There is growing evidence that the cognitive impairment of delirium is not entirely reversible in all patients, and it may be that delirium represents a time of significant risk for progression of underlying dementia. Preventive measures discussed in the text are, therefore, of particular importance in this population.
 ...
PMID:Delirium in the elderly. 913 98

Delirium is a common, serious problem for hospitalized older patients. Recognition of delirium poses challenges requiring cognitive assessment and knowledge of the clinical course. Delirium often is of multiple causes and is associated with a poor long-term prognosis. Nonpharmacologic approaches for delirium management are recommended; pharmacologic management should be reserved for patients who pose a danger to themselves or others. Importantly, delirium and its complications may be preventable through a targeted risk factor approach.
 ...
PMID:Delirium in hospitalized older patients. 979 77

1. Mental status changes are often the earliest indication of an untoward complication after transplantation. These may be obvious, such as hallucinations or paranoid delusions, or they may be subtle, appearing as changes in personality or motivation. 2. The three most common categories of neuropsychiatric posttransplant complications include the following: (1) concurrent pathological processes, such as mass lesion; (2) effects of vasoconstriction secondary to immunosuppressive medications; and (3) central nervous system pharmacodynamic effects of the immunosuppressive medications. 3. This differential diagnosis should guide the history as well as the mental status and neurological examinations. Suspected acute processes deserve computed tomography scanning. Magnetic resonance imaging, more sensitive to subtle structural change, should be generally reserved for cases suggesting such chronic change or those in which treatment appears ineffective. 4. Treatment follows the differential diagnosis. Concurrent diagnoses dictate specific treatment, such as in drainage of a subdural hematoma or administration of antibiotics for cerebral abscess. Symptoms referable to vasoconstriction suggest switching the primary immunosuppressive agent. Symptoms suggesting delirium indicate lowering the dosage of immunosuppressive medication, as in the case of generalized seizure, or use of very low-dose antipsychotic medication, as in cases of confusion, amotivational states, or personality changes.
 ...
PMID:Neuropsychiatric complications of liver and other solid organ transplantation. 1168 75

Sedatives continue to be used on a routine basis in critically ill patients. Although many agents are available and some approach an ideal, none are perfect. Patients require continuous reassessment of their pain and need for sedation. Pathophysiologic abnormalities that cause agitation, confusion, or delirium must be identified and treated before unilateral administration of potent sedative agents that may mask potentially lethal insufficiencies. The routine use of standardized and validated sedation scales and monitors is needed. It is hoped that reliable objective monitors of patients' level of consciousness and comfort will be forthcoming. Each sedative agent discussed in this article seems to have a place in the ICU pharmacologic armamentarium to ensure the safe and comfortable delivery of care. Etomidate is an attractive agent for short-term use to provide the rapid onset and offset of sedation in critically ill patients who are at risk for hemodynamic instability but seem to need sedation or anesthesia to perform a procedure or manipulate the airway. Ketamine administered through intramuscular injection or intravenous infusion provides quick, intense analgesia and anesthesia and allows patients to tolerate limited but painful procedures. The risk/benefit ratio associated with the use of this neuroleptic agent must be weighed carefully. Ketamine is contraindicated in patients who lack normal intracranial compliance or who have significant myocardial ischemia. Barbiturates are reserved mainly to induce coma in patients at risk for severe CNS ischemia, which frequently is associated with refractory intracranial hypertension, or in patients with status epilepticus. When administered in high doses, these drugs have prolonged sedative and depressant effects. Judicious hemodynamic monitoring is required when barbiturate coma is induced. Haloperidol is indicated in the treatment of delirium. Patients should be monitored for extrapyramidal side effects and, when they require higher doses, for potential electrocardiographic prolongation of the QT interval. Dexmedetomidine may evolve into an agent with qualities comparable with midazolam and propofol, and it may even become a drug of choice in select patients. Further study is required, however. Propofol has many of the qualities of an ideal sedative agent. Benzodiazepines and narcotics often are used in concert with propofol to provide reliable amnesia and to relieve pain, respectively. Propofol frequently causes hypotension when administered as a bolus or infusion, particularly in patients with limited cardiac reserve or hypovolemia. More data must be obtained to identify potential deleterious effects of hypertriglyceridemia, and further evaluation of the potential benefits in certain patient populations, such as neurosurgical patients, is needed.
 ...
PMID:Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. 1176 65

Psychosis only rarely occurs in patients with untreated Parkinson's disease. Much more commonly, psychosis is induced by drug therapy for Parkinson's disease and is the strongest known risk factor for nursing home placement. Delusions are less frequent than hallucinations, but are more concerning as they are often paranoid in nature. Treatment begins with a search for correctable infectious, toxic, and metabolic aetiologies. If symptoms persist, anti-Parkinson's disease medications are slowly reduced. However, withdrawal of these drugs usually worsens parkinsonism and is often not tolerated. Certain atypical antipsychotics can be used to treat psychosis without compromising motor function. The choice of atypical antipsychotic is largely based on ease of use and adverse effect profile as most have comparable efficacy in improving psychosis. Currently, there are five marketed atypical drugs - clozapine, risperidone, olanzapine, quetiapine and ziprasidone. Ziprasidone is the only agent whose adverse effect profile has not been reported in Parkinson's disease. The most common adverse effects of clozapine in Parkinson's disease are sedation, orthostatic hypotension and sialorrhoea. Sedation is generally helpful since these patients are frequently awake at night and tend to have worse behavioural problems then. Clozapine does not induce deterioration of motor function, but it has the potential to cause agranulocytosis, which is idiosyncratic and not dose-related. In risperidone-treated Parkinson's disease patients, reported adverse effects include somnolence, sialorrhoea, dizziness, palpitations, constipation, delirium, fatigue, leg cramps, depression, urinary incontinence and hypotension. Although in some Parkinson's disease studies, risperidone has been well tolerated, others have shown that many patients are unable to tolerate the drug due to deterioration of motor function. While an initial study of olanzapine in Parkinson's disease psychosis showed the drug to be effective without deterioration of motor function, succeeding reports demonstrated a deleterious effect of the drug on motor functioning. The most common adverse effects of quetiapine in Parkinson's disease patients are sedation and orthostatic hypotension. There is a lack of double-blind trials; however, cumulative reports involving >200 Parkinson's disease patients strongly suggest that quetiapine is well tolerated and effective. Unlike clozapine, it does not improve tremor and may induce mild deterioration of motor function. Recently, cholinesterase inhibitors have been reported to alleviate psychosis in Parkinson's disease. Although ondansetron, an antiemetic with antiserotonergic properties, has been reported to relieve psychosis in Parkinson's disease, its prohibitive cost has prevented further study in this population. Electroconvulsive treatment is generally reserved for the patient with psychotic depression who is unable to tolerate any pharmacological therapy.
 ...
PMID:Treatment of psychosis in Parkinson's disease: safety considerations. 1281 32

Recombinant preparations of the cytokine interferon (IFN)-alpha are increasingly used to treat a number of medical conditions, including chronic viral hepatitis and several malignancies. Although frequently effective, IFN alpha induces a variety of neuropsychiatric adverse effects, including an acute confusional state that develops rapidly after initiation of high-dose IFN alpha, a depressive syndrome that develops more slowly over weeks to months of treatment, and manic conditions most often characterised by extreme irritability and agitation, but also occasionally by euphoria. Acute IFN alpha-induced confusional states are typically characterised by disorientation, lethargy, somnolence, psychomotor retardation, difficulties with speaking and writing, parkinsonism and psychotic symptoms. Strategies for managing delirium should be employed, including treatment of contributing medical conditions, use of either typical or atypical antipsychotic agents and avoidance of medications likely to worsen mental status. Significant depressive symptoms occur in 21-58% of patients receiving IFN alpha, with symptoms typically manifesting over the first several months of treatment. The most replicated risk factor for developing depression is the presence of mood and anxiety symptoms prior to treatment. Other potential, but less frequently replicated, risk factors include a past history of major depression, being female and increasing IFN alpha dosage and treatment duration. The available data support two approaches to the pharmacological management of IFN alpha-induced depression: antidepressant pretreatment or symptomatic treatment once IFN alpha has been initiated. Pretreatment might be best reserved for patients already receiving antidepressants or for patients who endorse depression or anxiety symptoms of mild or greater severity prior to therapy. Several recent studies demonstrate that antidepressants effectively treat IFN alpha-induced depression once it has developed, allowing the vast majority of subjects to complete treatment successfully. Recent data suggest that IFN alpha-induced depression may be composed of two overlapping syndromes: a depression-specific syndrome characterised by mood, anxiety and cognitive complaints, and a neurovegetative syndrome characterised by fatigue, anorexia, pain and psychomotor slowing. Depression-specific symptoms are highly responsive to serotonergic antidepressants, whereas neurovegetative symptoms are significantly less responsive to these agents. These symptoms may be more effectively treated by agents that modulate catecholaminergic functioning, such as combined serotonin-noradrenaline (norepinephrine) antidepressants, bupropion, psychostimulants or modafinil. Additional factors to consider in selecting an antidepressant include potential drug-drug interactions and adverse effect profile. Finally, IFN alpha appears capable of inducing manic symptoms. Mania, especially when severe, is a clinical emergency. When this occurs, IFN alpha and antidepressants should be stopped, an emergency psychiatric consultation should be obtained, and treatment with a mood stabilizer should be initiated.
 ...
PMID:Neuropsychiatric adverse effects of interferon-alpha: recognition and management. 1569 25

Confusion is a frequent psychiatric and behavioural manifestation of diffuse cerebral injury found in elderly patients that are severely ill or stressed. The hyperactive form is often recognised because of the psychomotor agitation. However, the hypoactive form is most frequent and has a worse prognosis. Despite, it is often under-recognised. Among contributing factors, anticholinergic agents and drug interactions are significant. Identification and treatment of the underlying cause of delirium is essential with a focus on non pharmacological approach. Antipsychotic agents are reserved for severe forms and where non pharmacological intervention fracases.
 ...
PMID:[Delirium in old age. Difficulties in diagnosis]. 1905 26

Episodes of delirium are present in a significant number of hospitalised patients. Prevention is essential, because, when established, delirium has a negative impact on clinical outcomes (morbidity and mortality). Identifying at risk patients, monitoring predisposing and precipitating factors and intervening in a timely manner are all essential. In certain populations, such as elderly patients undergoing surgery, a specialized geriatrics consultation reduces the incidence of delirium. Pharmacological treatment is associated with adverse effects and should therefore be reserved for situations leading to impending danger to the patient or others. If such a treatment is indicated, the literature suggests that haloperidol is the antipsychotic of choice.
 ...
PMID:[A systematic approach to delirium]. 1991 89

Acute confusional state, delirium, occurs in up to 80% of patients in the intensive care unit and is also a common, life-threatening and potentially preventable clinical syndrome among persons who are 65 years of age or older in general hospital. The cause of acute confusional state is typically multifactorial. Delirium and dementia are highly interrelated and dementia is the leading risk factor for delirium. So the key steps to distinguish between delirium and behavioural and psychological symptoms of dementia are to address all evident causes, e.g. dementia, dehydration, infection, polymedication and to prevent complications and treat behavioral symptoms. First nonpharmacologic approaches should be instituted, including a calm, comfortable environment with the use of orienting influences. Pharmacologic management should be reserved for patients whose symptoms would threaten their own safety or the safety of other persons. Therapeutic drug options include modern antidepressants and neuroleptics.
 ...
PMID:[Delirium or behavioral and psychological symptoms of dementia in the elderly patient: diagnosis and treatment]. 2082 9


1 2 3 Next >>